Cited by 604Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedical Imaging Techniques and Applications

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study

Open access

Sabri, Osama, Sabbagh, Marwan N., Seibyl, John, Barthel, Henryk, Akatsu, Hiroyasu, Ouchi, Yasuomi, Senda, Kohei, Murayama, Shigeo, Ishii, Kenji, Takao, Masaki, Beach, Thomas G., Rowe, Christopher C., Leverenz, James B., Ghetti, Bernardino, Ironside, James W., Catafau, Ana M., Stephens, Andrew W., Mueller, Andre, Koglin, Norman, Hoffmann, Anja, Roth, Katrin, Reininger, Cornelia, Schulz‐Schaeffer, Walter J., Florbetaben Phase 3 Study Group·2015·Alzheimer's & Dementia

DOI 10.1016/j.jalz.2015.02.004

Open this paper in CoChat — free account Open PDF

Abstract

Background: Evaluation of brain β‐amyloid by positron emission tomography (PET) imaging can assist in the diagnosis of Alzheimer disease (AD) and other dementias. Methods: Open‐label, nonrandomized, multicenter, phase 3 study to validate the 18 F‐labeled β‐amyloid tracer florbetaben by comparing in vivo PET imaging with post‐mortem histopathology. Results: Brain images and tissue from 74 deceased subjects (of 216 trial participants) were analyzed. Forty‐six of 47 neuritic β‐amyloid‐positive cases were read as PET positive, and 24 of 27 neuritic β‐amyloid plaque‐negative cases were read as PET negative (sensitivity 97.9% [95% confidence interval or CI 93.8–100%], specificity 88.9% [95% CI 77.0–100%]). In a subgroup, a regional tissue‐scan matched analysis was performed. In areas known to strongly accumulate β‐amyloid plaques, sensitivity and specificity were 82% to 90%, and 86% to 95%, respectively. Conclusions: Florbetaben PET shows high sensitivity and specificity for the detection of histopathology‐confirmed neuritic β‐amyloid plaques and may thus be a valuable adjunct to clinical diagnosis, particularly for the exclusion of AD. Trial registration: ClinicalTrials.gov NCT01020838 .

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2015.02.004

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 4×
“Middle frontal gyrus Intense [19] 18/21 (85.”
Influential
Statistical Methods for Rates and Proportions.
Everitt, B. S., & Fleiss, J. L. (1981) · Biometrics · doi:10.2307/2530193 · Cited by 9,034
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citation
National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Self-citation
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G., & Heyman, A. (2002) · doi:10.1002/0470846410.ch42(iii · Cited by 2,859
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.
Scheltens, P., Leys, D., Barkhof, F., Huglo, D. G., Weinstein, H. C., Vermersch, P., Kuiper, M. A., Steinling, M., Wolters, E. C., & Valk, J. (1992) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.10.967 · Cited by 1,811
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117

Show all 33 references

Sorted by citations

Items 301–400 of 604

Deciphering the Structure and Formation of Amyloids in Neurodegenerative Diseases With Chemical Biology Tools
Landrieu, I., Dupré, E., Sinnaeve, D., Hajjar, L. E., & Smet‐Nocca, C. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.886382 · Cited by 12
Machine learning application for classification of Alzheimer's disease stages using 18F-flortaucipir positron emission tomography
Park, S. W., Yeo, N. Y., Lee, J., Lee, S.-H., Byun, J., Park, D. Y., Yum, S., Kim, J., Byeon, G., Kim, Y., et al. (2023) · BioMedical Engineering OnLine · doi:10.1186/s12938-023-01107-w · Cited by 14
Unraveling Alzheimer’s complexity with a distinct Aβ42 fibril type and specific AV-45 binding
Zhao, Q., Tao, Y., Yao, Y., Liu, K., Lv, S., Cui, B., Xiao, W., Cao, T., Li, W., Gao, F., et al. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-01921-4 · Cited by 14
The Role of Free and Cued Selective Reminding Test in Predicting [ 18 F]Florbetaben PET Results in Mild Cognitive Impairment and Mild Dementia
Spallazzi, M., Michelini, G., Barocco, F., Dieci, F., Copelli, S., Messa, G., Scarlattei, M., Pavesi, G., Ruffini, L., & Caffarra, P. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190950 · Cited by 11
Proteomic profiles of incident mild cognitive impairment and Alzheimer's disease among adults with Down syndrome
O’Bryant, S. E., Zhang, F., Silverman, W. P., Lee, J. H., Krinsky‐McHale, S. J., Pang, D. I., Hall, J. R., & Schupf, N. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12033 · Cited by 10
PET Radioligands for Imaging of Tau Pathology: Current Status
Choe, Y. S., & Lee, K.-H. (2015) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-015-0374-9 · Cited by 11
Histopathology and Florbetaben PET in Patients Incorrectly Diagnosed with Alzheimer’s Disease
Sabbagh, M. N., Schäuble, B., Anand, K., Richards, D., Murayama, S., Akatsu, H., Takao, M., Rowe, C. C., Masters, C. L., Barthel, H., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160821 · Cited by 11
Self-citation
Association between white matter lesions and cerebral glucose metabolism in patients with cognitive impairment
No, H.-J., Yi, H., Won, K. S., Chang, H. W., & Kim, H. W. (2019) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2019.01.005 · Cited by 11
Comparison of visual criteria for amyloid-PET reading: could criteria merging reduce inter-rater variability?
Paghera, B., Altomare, D., Peli, A., Morbelli, S. D., Buschiazzo, A., Bauckneht, M., Giubbini, R., Rodella, C. A., Camoni, L., Boccardi, M., et al. (2020) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.19.03124-8 · Cited by 12
Clinical Significance of Physical Frailty in Subjects With Subjective Cognitive Decline: A Prospective Study With Amyloid PET Data
Lim, E. Y., Ho, S. H., Hong, Y. J., Jeong, J. H., Park, H. K., Park, K. H., Kim, S., Wang, M. J., Choi, S. H., Shim, Y. S., et al. (2023) · Journal of Clinical Neurology · doi:10.3988/jcn.2022.0353 · Cited by 10
Dissociable spatial topography of cortical atrophy in early‐onset and late‐onset Alzheimer's disease: A head‐to‐head comparison of the LEADS and ADNI cohorts
Katsumi, Y., Touroutoglou, A., Brickhouse, M. J., Eloyan, A., Eckbo, R., Zaitsev, A., Joie, R. L., Lagarde, J., Schonhaut, D. R., Thangarajah, M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14489 · Cited by 12
Self-citation
Event-related potential markers of subjective cognitive decline and mild cognitive impairment during a sustained visuo-attentive task
Vergani, A. A., Mazzeo, S., Moschini, V., Burali, R., Lassi, M., Amato, L. G., Carpaneto, J., Salvestrini, G., Fabbiani, C., Giacomucci, G., et al. (2025) · NeuroImage Clinical · doi:10.1016/j.nicl.2025.103760 · Cited by 11
Amyloid PET and clinical management in a diverse, cognitively impaired population: The New IDEAS Study
Windon, C., Gatsonis, C. A., Carrillo, M. C., Romanoff, J., Hanna, L., Glavin, E. E., Gareen, I. F., Gutman, R., Hillner, B. E., March, A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70504 · Cited by 11
In Vivo and In Vitro Characteristics of Radiolabeled Vesamicol Analogs as the Vesicular Acetylcholine Transporter Imaging Agents
Ogawa, K., & Shiba, K. (2018) · Contrast Media & Molecular Imaging · doi:10.1155/2018/4535476 · Cited by 11
CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment
Brisson, M., Brodeur, C., Guillon, L. L., Masellis, M., Stoessl, A. J., Tamm, A., Zukotynski, K., Ismail, Z., Gauthier, S. G., Rosa‐Neto, P., et al. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12098 · Cited by 9
Relationship between F-18 florbetapir uptake in occipital lobe and neurocognitive performance in Alzheimer’s disease
Thientunyakit, T., Thongpraparn, T., Sethanandha, C., Yamada, T., Kimura, Y., Muangpaisan, W., & Ishii, K. (2021) · Japanese Journal of Radiology · doi:10.1007/s11604-021-01132-6 · Cited by 11
Self-citation
Customized FreeSurfer-based brain atlas for diffeomorphic anatomical registration through exponentiated lie algebra tool
Baek, M. S., Cho, H., Ryu, Y. H., & Lyoo, C. H. (2020) · Annals of Nuclear Medicine · doi:10.1007/s12149-020-01445-y · Cited by 10
Alteration of medial temporal lobe metabolism related to Alzheimer’s disease and dementia with lewy bodies
Kang, S. W., Jeon, S., Lee, Y., & Ye, B. S. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01429-4 · Cited by 9
Bifunctional Copper Chelators Capable of Reducing Aβ Aggregation and Aβ-Induced Oxidative Stress
Krasnovskaya, O. O., Abramchuk, D., Vaneev, A. N., Gorelkin, P. V., Abakumov, M. A., Timoshenko, R. V., Kuzmichev, I., Chmelyuk, N. S., Vadekhina, V. V., Kuanaeva, R. M., et al. (2024) · ACS Omega · doi:10.1021/acsomega.4c03152 · Cited by 10
Circulating medium‐ and long‐chain acylcarnitines are associated with plasma P‐tau181 in cognitively normal older adults
Sharmin, T., Chatterjee, P., Doecke, J. D., Ashton, N. J., Huynh, K., Pedrini, S., Sohrabi, H. R., Heng, B., Eslick, S., Zetterberg, H., et al. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16244 · Cited by 8
Aβ status assessment in a hypothetical scenario prior to treatment with disease‐modifying therapies: Evidence from 10‐year real‐world experience at university memory clinics
Brendel, M., Parvizi, T., Gnörich, J. S., Topfstedt, C. E., Büerger, K., Janowitz, D., Rauchmann, B., Perneczky, R., Kurz, C., Mehrens, D., et al. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70031 · Cited by 13
Findings of 18F‐PI ‐2620 tau PET imaging in patients with Alzheimer’s disease and healthy controls in relation to the plasma P‐tau181 levels in a Japanese sample
Bun, S., Moriguchi, S., Tezuka, T., Sato, Y., Takahata, K., Seki, M., Nakajima, S., Yamamoto, Y., Sano, Y., Suzuki, N., et al. (2022) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12281 · Cited by 8
Focal amyloid and asymmetric tau in an imaging-to-autopsy case of clinical primary progressive aphasia with Alzheimer disease neuropathology
Martersteck, A., Ayala, I., Ohm, D. T., Spencer, C., Coventry, C., Weintraub, S., Bigio, E. H., Mesulam, M. M., Geula, C., & Rogalski, E. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01412-w · Cited by 9
Brain Theranostics and Radiotheranostics: Exosomes and Graphenes In Vivo as Novel Brain Theranostics
Suh, M., & Lee, D. S. (2018) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-018-0550-9 · Cited by 8
Screening for Dementia Caused by Modifiable Lifestyle Choices Using Hybrid PET/MRI
Prato, F. S., Pavlosky, W. F., Foster, S. C., Thiessen, J. D., & Beaujot, R. (2019) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-180098 · Cited by 10
Toward Prevention and Reduction of Alzheimer’s Disease
González-Madrid, A., Calfío, C., González, A., Lüttges, V., & Maccioni, R. B. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230454 · Cited by 8
Positron Emission Tomography Molecular Imaging of the Major Neurodegenerative Disorders: Overview and Pictorial Essay, from a Nuclear Medicine Center's Perspective
Calabria, F. F., Leporace, M., Cimini, A., Ricci, M., Travascio, L., & Bagnato, A. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2206172 · Cited by 8
Traumatic Brain Injury and Alzheimer’s Disease Biomarkers: A Systematic Review of Findings from Amyloid and Tau Positron Emission Tomography
Dybing, K. M., Vetter, C. J., Dempsey, D. A., Chaudhuri, S., Saykin, A. J., & Risacher, S. L. (2024) · Journal of Neurotrauma · doi:10.1089/neu.2024.0055 · Cited by 9
Voiceprints of cognitive impairment: analyzing digital voice for early detection of Alzheimer’s and related dementias
Rezaii, N., Wong, B., Aisen, P., Beckett, L. A., Dage, J. L., Eloyan, A., Foroud, T., Womack, K. B., Carrillo, M. C., Kramer, J. H., et al. (2025) · npj Dementia · doi:10.1038/s44400-025-00040-0 · Cited by 8
Self-citation
Classification of 18F-Flutemetamol scans in cognitively normal older adults using machine learning trained with neuropathology as ground truth
Reinartz, M., Luckett, E. S., Schaeverbeke, J. M., Meyer, S. D., Adamczuk, K., Thal, D. R., Laere, K. V., Dupont, P. J., & Vandenberghe, R. R. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05808-7 · Cited by 8
Preclinical Evaluation of Novel PET Probes for Dementia
Cools, R., Kerkhofs, K., Leitao, R. C. F., & Bormans, G. M. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2023.03.004 · Cited by 9
Amyloid-β prediction machine learning model using source-based morphometry across neurocognitive disorders
Momota, Y., Bun, S., Hirano, J., Kamiya, K., Ueda, R., Iwabuchi, Y., Takahata, K., Yamamoto, Y., Tezuka, T., Kubota, M., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-58223-3 · Cited by 8
Radiopharmaceuticals for Assessment of Altered Metabolism and Biometal Fluxes in Brain Aging and Alzheimer’s Disease with Positron Emission Tomography
Xie, F., & Peng, F. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170280 · Cited by 8
Patient and Caregiver Assessment of the Benefits From the Clinical Use of Amyloid PET Imaging
Mustafa, R., Brosch, J. R., Rabinovici, G. D., Dickerson, B. C., Carrillo, M. C., Glazier, B. S., Gao, S., Tierney, M., Fargo, K. N., Austrom, M. G., et al. (2017) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000220 · Cited by 8
Associations of Salivary Total Antioxidant Capacity With Cortical Amyloid-Beta Burden, Cortical Glucose Uptake, and Cognitive Function in Normal Aging
Palomar-Bonet, M., Atienza, M., Hernández‐Ledesma, B., & Cantero, J. L. (2021) · The Journals of Gerontology Series A · doi:10.1093/gerona/glab034 · Cited by 8
Clinical Utility of β-Amyloid PET Imaging in People Living With HIV With Cognitive Symptoms
Vera, J. H., Eftychiou, N., Schürer, M., Rullmann, M., Barthel, H., Sabri, O., Gisslén, M., Zetterberg, H., Blennow, K., O’Brien, C., et al. (2021) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002648 · Cited by 8
Self-citation
Design, synthesis, and preliminary evaluation of [18F]-aryl flurosulfates PET radiotracers via SuFEx methods for β-amyloid plaques in Alzheimer’s disease
He, Y., Zhu, X., Wang, K., Xie, J.-K., Zhu, Z., Ni, M., Wang, S., & Xie, Q. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.117087 · Cited by 8
Amyloid positron emission tomography and cognitive reserve
Bauckneht, M., Picco, A., Nobili, F. M., & Morbelli, S. D. (2015) · World Journal of Radiology · doi:10.4329/wjr.v7.i12.475 · Cited by 8
A similarity-based approach to leverage multi-cohort medical data on the diagnosis and prognosis of Alzheimer's disease
Zhang, H., Zhu, F., Dodge, H. H., Higgins, G. A., Omenn, G. S., Guan, Y., & Initiative, T. A. D. N. (2018) · GigaScience · doi:10.1093/gigascience/giy085 · Cited by 7
Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria
Triviño‐Ibáñez, E. M., Sánchez-Vañó, R., Sopena‐Novales, P., Romero-Fábrega, J. C., Rodrı́guez-Fernández, A., Pardo, C. C., Lozano, M. D., & Gómez-Río, M. M. (2019) · Medicine · doi:10.1097/md.0000000000016509 · Cited by 8
Ageing stereotypes and prodromal Alzheimer’s disease (AGING): study protocol for an ongoing randomised clinical study
Gauthier, K., Morand, A., Dutheil, F., Alescio‐Lautier, B., Boucraut, J., Clarys, D., Eustache, F., Girard, N. J., Guedj, É., Mazerolle, M., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-032265 · Cited by 11
Comprehensive review on design perspective of PET ligands based on β-amyloids, tau and neuroinflammation for diagnostic intervention of Alzheimer’s disease
Mittal, P., Singh, N., Chaturvedi, S., Jyoti, A., Mishra, A. K., & Hazari, P. P. (2021) · Clinical and Translational Imaging · doi:10.1007/s40336-021-00410-7 · Cited by 9
Assessment of 18F-Florbetaben Amyloid PET Imaging in Patients with Suspected Alzheimer’s Disease and Isolated Increase in Cerebrospinal Fluid Tau Proteins
Manca, C., Hopes, L., Kearney‐Schwartz, A., Roch, V., Karcher, G., Baumann, C., Marie, P., Malaplate, C., Jonveaux, T., & Verger, A. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181146 · Cited by 8
Do Beliefs about the Pathogenetic Role of Amyloid Affect the Interpretation of Amyloid PET in the Clinic?
Boccardi, M., Altomare, D., Ferrari, C., Festari, C., Antelmi, L., Pievani, M., Tarallo, A., Muscio, C., Guerra, U. P., Paghera, B., et al. (2016) · Neurodegenerative Diseases · doi:10.1159/000439255 · Cited by 7
Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET—A Decade of Post-Authorization Insights
Jovalekic, A., Bullich, S., Roé-Vellvé, N., Kolinger, G. D., Howard, L. R., Elsholz, F., Lagos‐Quintana, M., Blanco-Rodriguez, B., Pérez-Martínez, E., Gismondi, R., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17121648 · Cited by 7
Self-citation
Cognitive and neurodegenerative trajectories of subjective cognitive decline according to baseline biomarkers: Results of the CoSCo study
Hong, Y. J., Choi, S. H., Kim, S.-Y., Jeong, J. H., Park, K. H., Wang, M. J., Kang, S. M., Yang, D. W., & CoSCo study group (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14473 · Cited by 7
Quantification of baseline amyloid PET in individuals with subjective cognitive decline can identify risk of amyloid accumulation and cognitive worsening: the FACEHBI study
Kolinger, G. D., Sotolongo‐Grau, Ó., Roé-Vellvé, N., Tartari, J. P., Sanabria, Á., Pérez-Martínez, E., Koglin, N., Stephens, A. W., Alegret, M., Tárraga, L., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07270-7 · Cited by 8
Self-citation
The intrinsic connectivity between the default mode and dorsal attention networks is an independent fMRI biomarker of Alzheimer's disease pathology burden
Lombardo, D., & Beckmann, C. F. (2025) · NeuroImage · doi:10.1016/j.neuroimage.2025.121509 · Cited by 7
Simplified Edinburgh and modified Boston criteria in relation to amyloid PET for lobar intracerebral hemorrhage
Michiels, L., Dobbels, L., Demeestere, J., Demaerel, P., Laere, K. V., & Lemmens, R. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103107 · Cited by 7
Amyloid-Positronenemissionstomographie mit [18 F]-Florbetaben in der Demenzdiagnostik
Schönecker, S., Prix, C., Raiser, T. M., Ackl, N., Wlasich, E., Stenglein‐Krapf, G., Mille, E., Brendel, M., Sabri, O., Patt, M., et al. (2016) · Der Nervenarzt · doi:10.1007/s00115-016-0249-z · Cited by 7
Self-citation
18F-labeled 2-phenylbenzoheterocycles with chiral dihydroxyl side chains as β-amyloid imaging probes
Li, Y., Zhou, K., Guo, W., & Cui, M. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115884 · Cited by 7
Imaging Clinical Subtypes and Associated Brain Networks in Alzheimer’s Disease
Herholz, K. (2022) · Brain Sciences · doi:10.3390/brainsci12020146 · Cited by 8
[18F]THK-5351 PET Patterns in Patients With Alzheimer’s Disease and Negative Amyloid PET Findings
Oh, M., Oh, J. S., Oh, S. J., Lee, S. J., Roh, J. H., Kim, W., Seo, H., Kang, J. M., Seo, S. W., Lee, J., et al. (2022) · Journal of Clinical Neurology · doi:10.3988/jcn.2022.18.4.437 · Cited by 8
Social Event Memory Test (SEMT): A Video-based Memory Test for Predicting Amyloid Positivity for Alzheimer’s Disease
Kim, K. W., Choi, J. D., Lee, N. K., Park, S., Park, S., Chin, J., Lee, B. H., Shin, J., Kim, Y., Jang, H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28768-1 · Cited by 7
Amyloid PETs are commonly negative in suspected Alzheimer’s disease with an increase in CSF phosphorylated-tau protein concentration but an Aβ42 concentration in the very high range: a prospective study
Manca, C., Jonveaux, T., Roch, V., Marie, P., Karcher, G., Lamiral, Z., Malaplate, C., & Verger, A. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09315-y · Cited by 7
A Modification of the Bielschowsky Silver Stain for Alzheimer Neuritic Plaques: Suppression of Artifactual Staining by Pretreatment with Oxidizing AgentsPreprint
Intorcia, A. J., Filon, J. R., Hoffman, B., Serrano, G. E., Sue, L. I., & Beach, T. G. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/570093 · Cited by 7
Self-citation
Image-and-Label Conditioning Latent Diffusion Model: Synthesizing A$\beta$-PET From MRI for Detecting Amyloid Status
Ou, Z., Pan, Y., Xie, F., Guo, Q., & Shen, D. G. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3492020 · Cited by 8
A brief history of Aβ imaging
Cohen, A. D., & Villemagne, V. L. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70291 · Cited by 7
Differential Diagnosis Between Alzheimer’s Disease-Related Depression and Pseudo-Dementia in Depression: A New Indication for Amyloid-β Imaging?
Leonhardi, J., Barthel, H., Speerforck, S., Dietzel, J., Schroeter, M. L., Saur, D., Tiepolt, S., Rullmann, M., Patt, M., Claßen, J., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215619 · Cited by 6
Self-citation
From clinical phenotype to proteinopathy: molecular neuroimaging in neurodegenerative dementias
Studart‐Neto, A., & Coutinho, A. M. (2022) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x-anp-2022-s138 · Cited by 6
Screening of [18F]Florbetazine for Aβ Plaques and a Head-to-Head Comparison Study with [11C]Pittsburgh Compound-B ([11C]PiB) in Human Subjects
Li, Y., Zhang, X., Zhao, H., Wang, Y., Zhang, D., Wang, X., Dong, R., Yan, X., Wu, J., Sui, Y., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00149 · Cited by 6
Use of biomarkers in the diagnosis of Alzheimer’s disease in adults with intellectual disability
McFeely, A., O’Connor, A., & Kennelly, S. (2024) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2024.100639 · Cited by 6
Unlocking ocular biomarkers for early detection of Alzheimer's disease
Dave, N., Lee, M., Pavlou, H., Im, O., Goh, K., Ulin, S., Malzbender, K., Shobin, E., & Sukumar, A. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14567 · Cited by 9
Multimodality Imaging Approaches in Alzheimer's disease. Part II: 1H MR spectroscopy, FDG PET and Amyloid PET
Promteangtrong, C., Kolber, M., Ramchandra, P., Moghbel, M. C., Houshmand, S., Schöll, M., Werner, T. J., Alavi, A. A., & Buchpiguel, C. A. (2015) · Dementia & Neuropsychologia · doi:10.1590/1980-57642015dn94000330 · Cited by 6
Genetic and degenerative disorders primarily causing dementia
Masdeu, J. C., & Pascual, B. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53485-9.00026-x · Cited by 6
Initial Physician Experience with [ 18 F]Flutemetamol Amyloid PET Imaging Following Availability for Routine Clinical Use in Japan
Hattori, N., Sherwin, P. F., & Farrar, G. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190150 · Cited by 6
Feasibility study of a PET-only amyloid quantification method: a comparison with visual interpretation
Shimokawa, N., Akamatsu, G., Kadosaki, M., & Sasaki, M. (2020) · Annals of Nuclear Medicine · doi:10.1007/s12149-020-01486-3 · Cited by 6
Colocalization of Tau but Not β-Amyloid with Cortical Superficial Siderosis in a Case with Probable CAA
Brendel, M., Catak, C., Beyer, L., Linn, J., Wahl, H., Janowitz, D., Rominger, A., Patt, M., Barthel, H., Sabri, O., et al. (2020) · Case Reports in Neurology · doi:10.1159/000506765 · Cited by 6
Self-citation
Association of TDP-43 Pathology with Global and Regional 18F-Florbetapir PET Signal in the Alzheimer’s Disease Spectrum
Teipel, S. J., Initiative, A. D. N., Temp, A. G. M., Levin, F., Dyrba, M., & Grothe, M. J. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201032 · Cited by 6
Development and Validation of a 18 F-Flortaucipir PET Visual Stratification Method
Tunali, I., Wang, J., Arora, A., Kim, M. J., Shcherbinin, S., Pontecorvo, M. J., & Iaccarino, L. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268700 · Cited by 5
Comparison of Amyloid-PET Analysis Software Using 18F-Florbetaben PET in Patients with Cognitive Impairment
Cheon, M., Yi, H., Ha, S., Kang, M. J., Jeong, D.-E., Abdelhafez, Y. G., & Nardo, L. (2025) · Diagnostics · doi:10.3390/diagnostics15162028 · Cited by 5
The Development of an Automatic Amyloid PET Quantification (AmPQ) Software with MR-based and MR-free Spatial Normalization
Huang, S., Lin, K., Lyu, Z.-J., & Hsiao, I. (2025) · Journal of Medical and Biological Engineering · doi:10.1007/s40846-025-00972-1 · Cited by 5
The Role of Thyroid Hormones in Neurodegenerative Disorders: Opportunities and Challenges
Zhang, Y., Hao, M., Li, Y., Cheng, K., & Zhang, C. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05290-w · Cited by 10
Associations of cerebrovascular disease and Alzheimer’s disease pathology with cognitive decline: Analysis of the National Alzheimer’s Coordinating Center Uniform Data Set
Chatterjee, A., Lee, S. Y., Diaz, V., Saloner, R., Sanderson‐Cimino, M. E., DeCarli, C. S., Maillard, P., Hinman, J. D., Vossel, K. A., Casaletto, K. B., et al. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.06.002 · Cited by 6
Harmonizing Aβ deposition threshold for 18F-florbetaben PET imaging: Addressing discrepancies and calibration between PET/CT and PET/MRI
Lin, H., Jiang, Q., Yang, Y., Huang, Q., Zhang, Y., Zhang, Z., Zhu, Y., Lu, J., Wang, J., Wang, M., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07279-y · Cited by 5
Evaluation of early-phase 18 F-Florbetaben PET as a surrogate biomarker of neurodegeneration: In-depth comparison with 18 F-FDG PET at group and single patient level
Lojo-Ramírez, J. A., Fernández‐Rodríguez, P., Guerra-Gómez, M., Marín-Cabañas, A. M., Macías, E. F., Jiménez-Hoyuela-García, J. M., & García-Solís, D. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251340380 · Cited by 5
Investigations of possible links between Alzheimer’s disease and type 2 diabetes mellitus by positron emission tomography: a systematic review
Piri, R., Naghavi‐Behzad, M., Gerke, O., Høilund‐Carlsen, P. F., & Vafaee, M. S. (2019) · Clinical and Translational Imaging · doi:10.1007/s40336-019-00339-y · Cited by 6
Distinct amyloid-dependent patterns of nigra dopamine depletion in Lewy body diseases
Baik, K., Cha, J., Park, M.-C., Lee, Y., Chung, S. J., Yoo, H. S., Sohn, Y. H., & Lee, P. H. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1196602 · Cited by 5
Dopamine transporter positron emission tomography in patients with Alzheimer’s disease with Lewy body disease features
Kang, S. W., Jeon, S., Lee, Y., & Ye, B. S. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.10.008 · Cited by 5
Towards multicenter β-amyloid PET imaging in mouse models: A triple scanner head-to-head comparison
Gnörich, J. S., Koehler, M., Wind-Mark, K., Klaus, C., Zatcepin, A., Palumbo, G., Lalia, M., Monasor, L. S., Beyer, L., Eckenweber, F., et al. (2024) · NeuroImage · doi:10.1016/j.neuroimage.2024.120748 · Cited by 6
Self-citation
Applied multimodal diagnostics in a case of presenile dementia
Schönecker, S., Brendel, M., Huber, M., Vollmar, C., Huppertz, H., Teipel, S. J., Okamura, N., Levin, J., Rominger, A., & Danek, A. (2016) · BMC Neurology · doi:10.1186/s12883-016-0647-7 · Cited by 5
Diagnostic de la maladie d’Alzheimer : apport de l’imagerie au florbétapir et autres radiopharmaceutiques de la plaque amyloïde
Semah, F., Deberdt, W. G., & Ceccaldi, M. P. (2016) · Médecine Nucléaire · doi:10.1016/j.mednuc.2016.08.001 · Cited by 5
The Role of Neuroimaging in the Assessment of the Cognitively Impaired Elderly
Kollack‐Walker, S., Liu, C. Y., & Fleisher, A. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.01.010 · Cited by 6
Challenges in Alzheimer’s Disease Diagnostic Work-Up: Amyloid Biomarker Incongruences
Lombardi, G., Pupi, A., Bessi, V., Polito, C., Padiglioni, S., Ferrari, C., Lucidi, G., Berti, V., Cristofaro, M. T. D., Piaceri, I., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200119 · Cited by 5
Clinicopathological Correlation: Dopamine and Amyloid PET Imaging with Neuropathology in Three Subjects Clinically Diagnosed with Alzheimer’s Disease or Dementia with Lewy Bodies
Gupta, H., Beach, T. G., Mehta, S. H., Shill, H. A., Driver‐Dunckley, E. D., Sabbagh, M. N., Belden, C. M., Liebsack, C., Dugger, B. N., Serrano, G. E., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200323 · Cited by 5
Self-citation
Molecular Imaging Biomarkers in Dementia: Amyloid and tau PET imaging aids evaluation of patients suspected of having Alzheimer disease or other dementias.
Dickerson, B. C., & Atri, A. (2020) · PubMed · Cited by 5
The Incremental Diagnostic Value of [18F]Florbetaben PET and the Pivotal Role of the Neuropsychological Assessment in Clinical Practice
Spallazzi, M., Barocco, F., Michelini, G., Morelli, N., Scarlattei, M., Baldari, G., Ruffini, L., & Caffarra, P. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180646 · Cited by 5
Can MRI T1 be used to detect early changes in 5xFAD Alzheimer’s mouse brain?
Spencer, N. G., Lovell, D. P., Elderfield, K., Austen, B., & Howe, F. A. (2016) · Magnetic Resonance Materials in Physics Biology and Medicine · doi:10.1007/s10334-016-0593-9 · Cited by 5
[18F]Florbetaben PET-CT confirms AL amyloidosis in a patient with Waldenström’s Macroglobulinemia
Fox, T. A., Lunn, M. P., Wechalekar, A. D., Bomanji, J. B., Wan, S., & D’Sa, S. (2018) · Haematologica · doi:10.3324/haematol.2017.184515 · Cited by 5
Re: Aducanumab-Related ARIA: Paean or Lament?
Wassef, H. R., & Colletti, P. M. (2022) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004490 · Cited by 5
Clinical Role of Brain PET in Alzheimer Disease in the Era of Disease-Modifying Therapies
Franceschi, A. M., Keir, G., Benzinger, T. L. S., Cogswell, P. M., Ali, F., Petrella, J. R., Prescott, J. W., Whitlow, C. T., Zaharchuk, G., Allen, J. W., et al. (2025) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8738 · Cited by 6
Calibration of multisite raters for prospective visual reads of amyloid PET scans
Soleimani‐Meigooni, D. N., Pezzoli, S., Blazhenets, G., Joie, R. L., Lin, Z., Soppe, C. L., Johnson, D. R., Koran, M. E. I., McConathy, J., Nasrallah, I. M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70732 · Cited by 4
Practical setting and potential applications of interventions guided by PET/MRI
Reich, C. M., Sattler, B., Jochimsen, T. H., Unger, M., Melzer, L., Landgraf, L., Barthel, H., Sabri, O., & Melzer, A. (2021) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.20.03293-8 · Cited by 4
Self-citation
A Longitudinal Study on Memory Enhancement in Subjective Cognitive Decline Patients: Clinical and Neuroimaging Perspectives
Na, S., Lee, C., Ho, S. H., Hong, Y. J., Jeong, J. H., Park, K. H., Kim, S., Wang, M. J., Choi, S. H., Han, S., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230667 · Cited by 4
Advances in Aβ Plaque Detection and the Value of Knowing: Overcoming Challenges to Improving Patient Outcomes in Alzheimer’s Disease
Jovalekic, A., Bullich, S., Catafau, A. M., & Santi, S. D. (2016) · Neurodegenerative Disease Management · doi:10.2217/nmt-2016-0026 · Cited by 4
Self-citation
Whole Brain Voxel-Wise Analysis of Cerebral Retention of Beta-Amyloid in Cognitively Normal Older Adults Using 18F-Florbetaben
Um, Y. H., Choi, W. H., Jung, W. S., Park, Y. H., Lee, C., & Lim, H. K. (2017) · Psychiatry Investigation · doi:10.4306/pi.2017.14.6.883 · Cited by 4
Asociación entre daños en la sustancia blanca y metabolismo de la glucosa cerebral en pacientes con disfunción cognitiva
No, H.-J., Yi, H.-A., Won, K. S., Chang, H. W., & Kim, H. W. (2019) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2018.12.001 · Cited by 4
Effect of Alzheimer’s Disease and Lewy Body Disease on Metabolic Changes
Lee, Y. H., Jeon, S., Yoo, H. S., Chung, S. J., Jung, J. H., Baik, K., Sohn, Y. H., Lee, P. H., Yun, M., Evans, A. C., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201094 · Cited by 4
Correlation between brain glucose metabolism (18F-FDG) and cerebral blood flow with amyloid tracers (18F-Florbetapir) in clinical routine: Preliminary evidences
Albano, D., Premi, E., Peli, A., Camoni, L., Bertagna, F., Turrone, R., Borroni, B., Calhoun, V. D., Rodella, C. A., Magoni, M., et al. (2021) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2021.03.016 · Cited by 4
Non-standard pipeline without MRI has replicability in computation of Centiloid scale values for PiB and 18F-labeled amyloid PET tracers
Fujishima, M., & Matsuda, H. (2022) · Neuroimage Reports · doi:10.1016/j.ynirp.2022.100101 · Cited by 4

Authors: Sabri, O., Sabbagh, M. N., Seibyl, J., Barthel, H., Akatsu, H., Ouchi, Y., Senda, K., Murayama, S., Ishii, K., Takao, M., Beach, T. G., Rowe, C. C., Leverenz, J. B., Ghetti, B., Ironside, J. W., Catafau, A. M., Stephens, A. W., Mueller, A., Koglin, N., Hoffmann, A., Roth, K., Reininger, C., Schulz‐Schaeffer, W. J., & Florbetaben Phase 3 Study Group
Affiliations: University Hospital Leipzig (DE)
Banner Sun Health Research Institute (US)
Molecular Neuroimaging LLC New Haven CT USA
Nagoya City University (JP)
Hamamatsu University (JP)
Koseikai Hospital Toyohashi Japan
Tokyo Metropolitan Institute of Gerontology (JP)
Institute of Brain and Blood Vessels (JP)
The University of Melbourne (AU)
University of Washington (US)
Indiana University Indianapolis (US)
University of Edinburgh (GB)
Piramal (Germany) (DE)
Piramal Imaging GmbH Berlin Germany
Bayer (Germany) (DE)
Universitätsmedizin Göttingen (DE)
Corresponding author: Sabri, Osama
ORCID: Sabri, Osama
Sabbagh, Marwan N.
Seibyl, John
Barthel, Henryk
Akatsu, Hiroyasu
Ouchi, Yasuomi
Murayama, Shigeo
Ishii, Kenji
Takao, Masaki
Beach, Thomas G.
Rowe, Christopher C.
Leverenz, James B.
Ghetti, Bernardino
Ironside, James W.
Stephens, Andrew W.
Koglin, Norman
Roth, Katrin
Schulz‐Schaeffer, Walter J.
Venue: Alzheimer's & Dementia
Publisher: Wiley
Published: 2015-03-27
Volume: 11
Issue: 8
Pages: 964-974
ISSN: 1552-5260 (ISSN-L)
1552-5279
DOI: 10.1016/j.jalz.2015.02.004
OpenAlex: W2169508236
Cited by: 602
References: 33
Citations by year: 2026: 57 · 2025: 64 · 2024: 59 · 2023: 50 · 2022: 56 · 2021: 64 · 2020: 61 · 2019: 46 · 2018: 42 · 2017: 47 · 2016: 42 · 2015: 13
FWCI: 39.00
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Alzheimer s & Dementia (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
GRO (submittedVersion)
Funders: Bioscript Medical
Piramal Imaging S.A
Bayer Pharma AG
Piramal Imaging S.A.
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords: florbetaben, amyloid PET
MeSH terms: Aged, Aged, 80 and over, Alzheimer Disease, Analysis of Variance, Aniline Compounds, Brain, Diagnosis, Female, Humans, Image Processing, Computer-Assisted, Magnetic Resonance Imaging, Male, Middle Aged, Psychiatric Status Rating Scales, Radiography, ROC Curve, Stilbenes, Cohort Studies, Amyloid beta-Peptides, Positron-Emission Tomography, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks